BackKintor Pharmaceutical Limited Overview

Kintor Pharmaceutical Limited Total Current Liabilities

Latest total current liabilities for KNTPF: $180M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$182.92M
↑ 27.97% YoYΔ $39.98M vs prior year quarter

Peer trimmed avg / median

Loading

Kintor Pharmaceutical Limited Total Current Liabilities History

Loading

Kintor Pharmaceutical Limited vs. peers: Total Current Liabilities Comparison

Loading

Kintor Pharmaceutical Limited Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Kintor Pharmaceutical Limited (KNTPF) FAQ

Kintor Pharmaceutical Limited's total current liabilities stands at $180M as of June 2026. That compares with $140M in the prior-year period — up 28.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Kintor Pharmaceutical Limited reported $180M in total current liabilities versus $140M a year earlier — a 28.0% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $140M in the prior-year period — up 28.0% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Kintor Pharmaceutical Limited's total current liabilities evolved across reporting periods, while the comparison chart places KNTPF next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Kintor Pharmaceutical Limited's reading of $180M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.